Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORTREL 7/7/7 vs ADQUEY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin oral contraceptive. Suppresses gonadotropin release, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial receptivity.
ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.
Prevention of pregnancy
Alzheimer disease (FDA approved for treatment of mild cognitive impairment or mild dementia stage),Off-label: none established
One tablet orally once daily, taken at the same time each day. Each tablet contains norethindrone 0.5 mg/ethinyl estradiol 35 mcg for days 1-7, norethindrone 0.75 mg/ethinyl estradiol 35 mcg for days 8-14, and norethindrone 1 mg/ethinyl estradiol 35 mcg for days 15-21, followed by 7 placebo tablets.
400 mg orally once daily with food.
Norelgestromin terminal half-life is approximately 28 hours; ethinyl estradiol terminal half-life is approximately 17 hours. The extended half-life supports once-weekly dosing.
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min)
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes first-pass metabolism. Norethindrone: metabolized by reduction and conjugation; primarily via CYP3A4.
Metabolized via catabolic pathways similar to endogenous Ig G; no specific cytochrome P450 enzyme involvement.
Renal excretion of metabolites (primarily ethinyl estradiol and norelgestromin conjugates) accounts for approximately 50% of elimination; fecal/biliary excretion accounts for the remainder (about 35-40% fecal, 10-15% biliary).
Renal: 70-80% unchanged; Fecal: 5-10% as metabolites; Biliary: minimal (<2%)
Norelgestromin is 99% bound primarily to albumin and sex hormone-binding globulin; ethinyl estradiol is 98% bound primarily to albumin.
98% bound to albumin
Norelgestromin apparent Vd/F is approximately 2.1 L/kg; ethinyl estradiol apparent Vd/F is approximately 5.5 L/kg, indicating extensive tissue distribution.
0.2-0.3 L/kg; indicates limited extravascular distribution
Transdermal bioavailability of norelgestromin and ethinyl estradiol is approximately 60-65% relative to oral administration due to avoidance of first-pass metabolism.
Oral: 85-90%; IM: 95-100%
No dose adjustment recommended for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential for decreased drug elimination and hormonal alterations.
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: 200 mg daily; Cr Cl <30 m L/min: 100 mg daily; hemodialysis: 100 mg daily after dialysis.
Contraindicated in acute hepatic disease or severe hepatic insufficiency (Child-Pugh class C). For Child-Pugh class A or B, use with caution; consider alternative contraception due to possible impaired hormone metabolism. No specific dose adjustment guidelines available.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg daily; Child-Pugh C: not recommended.
Safety and efficacy in postmenarchal pediatric patients have been established. Dose is the same as for adults: one tablet orally once daily following the 28-day regimen.
Weight ≥10 kg: 12 mg/kg/dose twice daily; weight <10 kg: 8 mg/kg/dose twice daily.
Not indicated for use in postmenopausal women. No studies in geriatric population; use is not appropriate due to lack of need for contraception.
Initial dose 200 mg daily; titrate based on renal function; monitor for neuropsychiatric effects.
Cigarette smoking increases risk of serious cardiovascular events. Use is contraindicated in women over 35 who smoke.
Amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition), can occur. ARIA is usually asymptomatic but serious events including seizure and status epilepticus have been reported. Patients with apolipoprotein E ε4 homozygosity have a higher incidence of ARIA.
Increased risk of thromboembolic disorders, myocardial infarction, stroke, hepatic neoplasia, gallbladder disease. Discontinue if jaundice, visual disturbances, or migraine occurs. Blood pressure should be monitored.
1) Amyloid-related imaging abnormalities (ARIA): monitor with MRI before and during treatment; consider dose interruption or discontinuation if severe. 2) Hypersensitivity reactions: angioedema, urticaria reported. 3) Risk of falls due to cognitive impairment. 4) No head-to-head trials showing superiority over other treatments.
Thrombophlebitis, thromboembolic disorders, cerebral vascular disease, coronary artery disease, known or suspected pregnancy, undiagnosed abnormal genital bleeding, known or suspected breast cancer, liver tumor or active liver disease, hypersensitivity to components, and women over 35 who smoke.
History of severe hypersensitivity to aducanumab or any excipients in ADQUEY.
No significant food interactions. Grapefruit juice may slightly increase estrogen exposure but not considered clinically relevant. Avoid herbal supplements such as St. John's wort, which can reduce contraceptive efficacy.
Avoid grapefruit and grapefruit juice; may increase drug levels. High-fat meals can increase absorption; take with food or on an empty stomach consistently.
First trimester: No known association with major congenital anomalies based on population data. However, exposure to ethinyl estradiol and norethindrone acetate is not recommended during pregnancy due to theoretical risks from hormonal exposure. Second and third trimesters: Not indicated for use; hormonal contraceptives should be discontinued if pregnancy occurs. No evidence of fetal harm from inadvertent use early in pregnancy.
ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may lead to feminization of male fetuses and other adverse outcomes.
Combined hormonal contraceptives may reduce milk production and pass into breast milk. The M/P ratio for ethinyl estradiol is approximately 0.3-0.5; for norethindrone, minimal transfer. Use is generally not recommended during breastfeeding, especially in the early postpartum period. Alternative contraception advised.
Excretion into breast milk is minimal; however, ADQUEY may reduce milk production and quality. M/P ratio not established. Avoid use during breastfeeding.
Contraindicated during pregnancy. No pharmacokinetic studies in pregnant women; no dose adjustments needed as drug is discontinued. Standard dosing for non-pregnant women: 7 tablets of 0.035 mg ethinyl estradiol/0.5 mg norethindrone, then 7 tablets of 0.035 mg EE/0.75 mg NE, then 7 tablets of 0.035 mg EE/1 mg NE.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue immediately if pregnancy occurs.
NORTREL 7/7/7 is a triphasic oral contraceptive. The 7/7/7 dosing (7 days of 35 mcg EE/0.5 mg norethindrone, 7 days of 35 mcg EE/0.75 mg norethindrone, 7 days of 35 mcg EE/1 mg norethindrone) mimics natural cycle. Missed dose management: if missed one active pill, take as soon as remembered; if missed two or more, use backup contraception for 7 days and consider emergency contraception. Breakthrough bleeding is common in first 3 cycles. Drug interactions: rifampin, certain anticonvulsants, and some antibiotics may reduce efficacy. Contraindicated in women with migraines with aura, history of DVT/PE, active liver disease, or breast cancer. Monitor blood pressure at baseline and follow-up.
Administration with a full glass of water and staying upright for 30 minutes reduces risk of esophagitis. Monitor for cutaneous lupus erythematosus and Stevens-Johnson syndrome. Avoid concomitant use with drugs that prolong QT interval due to risk of torsades de pointes.
Take one pill daily at the same time each day, following the 7/7/7 sequence.,Missed pill instructions: if you miss one active pill, take it as soon as you remember and continue the pack; if you miss two or more active pills, take the most recent missed pill, discard others, use backup contraception for 7 days, and consider emergency contraception.,Common side effects include nausea, breast tenderness, breakthrough bleeding, and mood changes; these often improve after 3 cycles.,Seek emergency care if you experience leg pain/swelling, chest pain, sudden severe headache, or vision changes, which may signal a blood clot.,Smoking increases the risk of serious cardiovascular side effects, especially if you are over 35 years old.,Tell your doctor about all medications you take, including antibiotics and herbal supplements like St. John's wort.,If you miss a period, take a pregnancy test and contact your doctor.
Take exactly as prescribed; do not double doses if missed.,Swallow tablet whole; do not crush or chew.,Avoid direct sunlight; use sunscreen and protective clothing.,Report any skin rash, blisters, or eye irritation immediately.,Do not take with antacids, iron supplements, or sucralfate; separate by at least 4 hours.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORTREL 7/7/7 vs ADQUEY, answered by our medical review team.
NORTREL 7/7/7 is a Oral Contraceptive that works by Combination estrogen-progestin oral contraceptive. Suppresses gonadotropin release, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial receptivity.. ADQUEY is a Oral Contraceptive that works by ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORTREL 7/7/7 and ADQUEY depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORTREL 7/7/7 is: One tablet orally once daily, taken at the same time each day. Each tablet contains norethindrone 0.5 mg/ethinyl estradiol 35 mcg for days 1-7, norethindrone 0.75 mg/ethinyl estradiol 35 mcg for days 8-14, and norethindrone 1 mg/ethinyl estradiol 35 mcg for days 15-21, followed by 7 placebo tablets.. The standard adult dose of ADQUEY is: 400 mg orally once daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORTREL 7/7/7 and ADQUEY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORTREL 7/7/7 is classified as Category C. First trimester: No known association with major congenital anomalies based on population data. However, exposure to ethinyl estradiol and norethindrone acetate is not recommended . ADQUEY is classified as Category C. ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Sec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.